NEW YORK ( F.A.S.T. Graphs) -- Of late I have been drawing article ideas from TheStreet.com's founder Jim Cramer. Specifically, I find a tidbit from Cramer's CNBC show "Mad Money" and I expand upon his underlying thesis.
Granted, even my articles come with the caveat of "further due diligence required," but I always believe it's prudent to understand the logic behind a simple one sentence answer. In the past six weeks I have focused on Walgreen (WAG), CVS (CVS), Nike (NKE), Exxon Mobil (XOM) and Chevron (CVX).
Today, I would like to take a closer look at health care stalwart Johnson & Johnson (JNJ - Get Report). The specific question on Johnson & Johnson came within the Wednesday's "Lightning Round" segment of the show.
Cramer indicated: "I think you should wait until $85, but this one is a buy."As with my previous posts, we happen to share a similar ideology. However, a further look as to why it might be a sensible statement seems like a logical next step. Luckily, the powerful Fundamentals Analyzer Software Tool of F.A.S.T. Graphs can make this process interesting and efficient. The following Earnings and Price Correlated F.A.S.T. Graph is truly something to behold. Notice that the price and normal P/E ratio has been removed so that we can begin by focusing on the business results of the company only. We see that operating earnings (orange line) have grown at almost 10% a year for the last decade and a half. In addition, we can observe that Johnson & Johnson has not only paid but also increased its dividend (pink line) every year. Further, not only has Johnson & Johnson increased its dividend for the last 15 years but, more impressively, this increase streak has been going on for 51 consecutive years. If you're looking for consistency, one would be hard-pressed to find a better looking operating company. Of course, the underlying reasons behind Johnson & Johnson's success are pretty easy to figure out: the company consistently sells more stuff, has wide margins and has demonstrated an ability to be good stewards of capital. With regard to sales per share, Johnson & Johnson has been able to increase revenue in all but one of the last 15 years. In turn, common equity per share, or book value (ceqps) has grown a solid clip of just over 11% a year.